“…In addition, the ability of mixed inocula of tumour cells and ds-RNA to induce tumour specific immunity, and their suitability as a vaccine for active immunotherapy, have been assessed, particularly in comparison with previous studies with BCG and tumour cell mixed inocula (Baldwin and Pimm, 1973a . Hepatoma D23, induced by oral administration of 4-dimethylaminoazobenzene, is also immunogenic, producing resistance following graft excision to challenge with up to 5 x 105 tumour cells (Baldwin and Barker, 1967;Price and Baldwin, 1974). Mammary carcinoma AAF57 induced by repeated intraperitioneal injection of N-hydroxy-2-acetylaminofluorene lacks detectable immunogenicity, excision of subcutaneous grafts failing to elicit resistance to challenge with 1 x 103 cells, this being the minimum inoculum for growth in control rats (Baldwin and Embleton, 1974).…”